Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $40.00 at Scotiabank

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target lifted by Scotiabank from $35.00 to $40.00 in a report released on Thursday,Benzinga reports. Scotiabank currently has a sector outperform rating on the stock.

Several other equities analysts have also issued reports on the stock. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, December 22nd. Barclays began coverage on Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price objective for the company. Jefferies Financial Group boosted their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, The Goldman Sachs Group raised their price target on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Buy” and an average price target of $35.67.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $33.04 on Thursday. The company has a market capitalization of $37.90 billion, a PE ratio of 27.54, a P/E/G ratio of 1.89 and a beta of 0.66. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. The company has a 50-day simple moving average of $30.29 and a two-hundred day simple moving average of $23.03. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $33.44.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 48.20%. The company’s revenue was up 11.4% compared to the same quarter last year. During the same period last year, the business earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Research analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the transaction, the director directly owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. This trade represents a 28.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the sale, the insider owned 52,828 shares of the company’s stock, valued at approximately $1,517,748.44. The trade was a 80.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 622,060 shares of company stock valued at $17,076,965. 0.49% of the stock is owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Grove Bank & Trust lifted its position in Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares during the period. Cromwell Holdings LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares during the period. Advisors Asset Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $41,000. Rothschild Investment LLC boosted its stake in shares of Teva Pharmaceutical Industries by 97.0% in the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after buying an additional 1,348 shares during the last quarter. Finally, JFS Wealth Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 257.1% during the third quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after acquiring an additional 2,000 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results materially beat expectations — EPS $0.96 vs. $0.65 consensus and revenue $4.71B vs. $4.36B; management highlighted branded-drug strength (notably Austedo) and a Sanofi milestone that lifted the quarter. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Fourth-quarter profit/revenue rise story notes the milestone payment that kicked off a late‑stage IBD study and helped drive results — supports the case for durable branded-product growth. Teva Pharmaceutical profit, revenue rise in fourth quarter
• Positive Sentiment: Analysts raised targets: Truist bumped its target to $38 (buy) and Scotiabank to $40 (sector outperform), signaling dealer confidence in upside from the beat and pipeline progress. Benzinga TickerReport — Scotiabank target raise
• Positive Sentiment: Company highlights 3rd consecutive year of growth (2025 revenues $17.3B) and positions its pipeline as value‑creating, which supports a longer‑term growth narrative beyond near‑term guidance. GlobeNewswire — Teva delivers 3 consecutive years of growth
• Neutral Sentiment: Company released the earnings slide deck and hosted an earnings call — useful for investors wanting details on segment trends, pipeline timelines and margin assumptions. MarketBeat — Earnings materials
• Neutral Sentiment: Seeking Alpha published the Q4 earnings call transcript and the results presentation for investors who want full management commentary and Q&A. SA — Earnings call transcript SA — Presentation
• Neutral Sentiment: PR/awareness activity (Will Forte campaign about Huntington’s disease) may raise public awareness but is unlikely to move near‑term fundamentals materially. Yahoo Finance — Will Forte Teams Up with Teva
• Negative Sentiment: FY‑2026 guidance is cautious on revenue: EPS guidance of 2.57–2.77 is roughly in line with consensus, but the revenue range of $16.4–16.8B sits below the ~$17.0B street estimate — investors may view this as a near‑term headwind despite the quarter’s beat.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.